Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study

Warnecke, Christine; Manousaridis, Ioannis; Herr, Raphael M.; Terris, Darcey D.; Goebeler, Matthias; Goerdt, Sergij; Peitsch, Wiebke K.

doi:10.1684/ejd.2011.1467

Cited by 35 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Twenty‐nine papers concerning adiponectin and psoriasis were retrieved, and 14 studies were included for date extraction . In the process of data extraction, we found that the studies of Ozdemir et al .…”

Section: Resultsmentioning

confidence: 99%

Adiponectin levels in patients with psoriasis: A meta‐analysis

Zhu¹,

Shi²,

Zhang

et al. 2013

The Journal of Dermatology

View full text Add to dashboard Cite

Conflicting results regarding adiponectin levels in patients with psoriasis have been reported. We carried out a meta-analysis on studies which compared adiponectin levels of psoriatic patients with controls. A published work search was performed through PubMed (MEDLINE), EMBASE and the Cochrane Library for articles published in English. Pooled standardized mean difference (SMD) and 95% confidence intervals (95% CI) were calculated by using random effects and fixed effect models. Heterogeneity between studies was assessed using the Cochran's Q and I(2) statistics. A total of nine studies were enrolled (389 cases and 360 controls) for adiponectin, and three studies were included (132 cases and 132 controls) for high-molecular weight (HMW) adiponectin. Adiponectin and HMW adiponectin levels were not significantly different in patients with psoriasis compared with controls (SMD, -0.151 [95% CI, -0.616 to 0.315]; P = 0.526 for adiponectin; SMD, 0.999 [95% CI, -2.626 to 4.624]; P = 0.589 for HMW adiponectin). The associations were borderline significantly different in the stratum of those with a mean age of less than 40 years (SMD, -0.516 [95% CI: -1.032 to 0]; P = 0.050). Sensitivity analyses were not substantially altered in the direction of effect when any one study was excluded. No publication bias was detected. The level of adiponectin and HMW adiponectin may not be associated with psoriasis. The relationship between psoriasis and adipokines needs more in-depth studies with larger sample sizes.

show abstract

Section: Resultsmentioning

confidence: 99%

Adiponectin levels in patients with psoriasis: A meta‐analysis

Zhu¹,

Shi²,

Zhang

et al. 2013

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…When compared with control populations (see below), patients with psoriasis had a higher likelihood of hypertension, dyslipidaemia, diabetes, obesity smoking, renal disease and metabolic syndrome . However, control groups in these studies included people with ‘forms of dermatitis’, other hospitalized patients and people taking part in other research projects, which makes interpretation, comparison and clinical implications uncertain.…”

Section: Discussionmentioning

confidence: 99%

Primary care‐based screening for cardiovascular risk factors in patients with psoriasis

et al. 2016

View full text Add to dashboard Cite

SummaryBackgroundStudies assessing cardiovascular disease (CVD) risk factors in patients with psoriasis have been limited by selection bias, inappropriate controls or a reliance on data collected for clinical reasons.ObjectivesTo investigate whether screening for CVD risk factors in patients with psoriasis in primary care augments the known prevalence of CVD risk factors in a cross‐sectional study.MethodsPatients listed as having psoriasis in primary care were recruited, screened and risk assessed by QRISK2.ResultsIn total, 287 patients attended (mean age 53 years, 57% women, 94% white British, 22% severe disease, 33% self‐reported psoriatic arthritis). The proportion with known and screen‐detected (previously unknown) risk factors was as follows: hypertension 35% known and 13% screen‐detected; hypercholesterolaemia 32% and 37%; diabetes 6·6% and 3·1% and chronic kidney disease 1·1% and 4·5%. At least one screen‐detected risk factor was found in 48% and two or more risk factors were found in 21% of patients. One in three patients (37%) not previously known to be at high risk were found to have a high (> 10%) 10‐year CVD risk. Among the participants receiving treatment for known CVD risk factors, nearly half had suboptimal levels for blood pressure (46%) and cholesterol (46%).ConclusionsCardiovascular risk factor screening of primary care‐based adults with psoriasis identified a high proportion of patients (i) at high CVD risk, (ii) with screen‐detected risk factors and (iii) with suboptimally managed known risk factors. These findings need to be considered alongside reports that detected limited responses of clinicians to identified risk factors before universal CVD screening can be recommended.

show abstract

“…[14][15][16][17][18][19][20][21][22][23][24][25][26] Adiponectin has been negatively correlated with PASI (r = À0.34, P < 0.05) 17,19 and TNF-a levels (r = À0.64, P < 0.01). [14][15][16][17][18][19][20][21][22][23][24][25][26] Adiponectin has been negatively correlated with PASI (r = À0.34, P < 0.05) 17,19 and TNF-a levels (r = À0.64, P < 0.01).…”

Section: Obesity Weight Loss and Psoriasismentioning

confidence: 98%

Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction

et al. 2017

View full text Add to dashboard Cite

Adipokines are secreted by white adipose tissue, an active endocrine organ, and play a role in the regulation of metabolic functions such as lipid metabolism, inflammation, and vascular homeostasis. Adipokines are secreted in excess in obesity and contribute to the development of associated comorbidities such as metabolic syndrome and atherosclerosis. Psoriasis, a chronic immune-mediated skin disease, is associated with obesity and increased cardiovascular risk. Understanding the role of adipokines in psoriasis may in part explain the association between psoriasis and cardiovascular disease. This review summarizes the data regarding key adipokines in patients with psoriasis and the change in adipokine profiles with psoriasis therapy. Adipokines may be mediators of cutaneous inflammation suggesting a role in the pathophysiology of psoriasis and the development of comorbidities.

show abstract

Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study

Cited by 35 publications

References 0 publications

Adiponectin levels in patients with psoriasis: A meta‐analysis

Adiponectin levels in patients with psoriasis: A meta‐analysis

Primary care‐based screening for cardiovascular risk factors in patients with psoriasis

Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction

Contact Info

Product

Resources

About